Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
Non-Tubercular Mycobacteria
What alternative treatment regimen do you recommend for patients with Mycobacterium kansasii lung infection who can no longer tolerate ethambutol due to drug toxicities?
Related Questions
Do you routinely give prophylactic antibiotics prior to ERCP for biliary obstruction in light of recent studies suggesting reduction of periprocedural infection?
What is your preferred method for latent tuberculosis screening prior to outpatient hemodialysis initiation for a patient with new dialysis requirements?
When would you consider long-term suppressive antibiotic therapy in patients with chronic or recurrent bacterial prostatitis who continue to experience symptoms despite multiple courses of antibiotics?
Would you give long term antistreptococcal antibiotic prophylaxis to a patient who presents with features of poststreptococcal reactive arthritis but who also meets criteria for Acute Rheumatic Fever?
Would you still consider adding clindamycin for streptococcal toxic shock syndrome in situations where the isolate is considered to be resistant?
What is your approach to antibiotic prophylaxis for spontaneous bacterial peritonitis in patients with cirrhosis?
How extensive of an infectious workup would you consider appropriate for a nursing home resident with dementia who is otherwise healthy, has a fever, is hemodynamically stable, and without localizing signs or symptoms?
How would you approach a young patient with sickle cell disease without a history of frequent vaso-occlusive crises, admitted with high fever, vague back/flank pain and mild LUQ abdominal tenderness, marked leukocytosis, no respiratory symptoms, and negative chest x-rays and CT abdomen and pelvis with contrast?
What patient factors influence your decision between prescribing oral pre-exposure prophylaxis and long-acting injectable PrEP for HIV prevention?
For a patient on appropriate treatment for invasive aspergillosis, how do you determine if and when it is acceptable to reintroduce a TNF inhibitor that likely contributed to their acquisition of the infection but is considered essential for control of their inflammatory condition?
